CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Report for D018805: Sepsis NIH

(Synonyms: Sepsi, Sepsis)

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (5)


Name (Synonyms) Correlation
drug1410 Toraymyxin PMX-20R (PMX Cartridge) Wiki 0.58
drug1139 Recombinant human alkaline phosphatase Wiki 0.58
drug1552 draw blood Wiki 0.58
drug50 Acalabrutinib Wiki 0.41
drug1016 Placebo Wiki 0.04

Correlated MeSH Terms (6)


Name (Synonyms) Correlation
D012772 Shock, Septic NIH 0.58
D019446 Endotoxemia NIH 0.58
D012769 Shock, NIH 0.29
D058186 Acute Kidney Injury NIH 0.19
D045169 Severe Acute Respiratory Syndrome NIH 0.03
D018352 Coronavirus Infections NIH 0.03

Correlated HPO Terms (1)


Name (Synonyms) Correlation
HP:0100806 Sepsis HPO 0.82

There are 3 clinical trials

Clinical Trials


1 Evaluating the Use of Polymyxin B Cartridge Hemoperfusion for Patients With Septic Shock and COVID 19

Prospective, observational, clinical investigation of PMX cartridge use in COVID 19 patients with septic shock

NCT04352985 Septic Shock Endotoxemia COVID Corona Virus Infection Sepsis, Severe Device: Toraymyxin PMX-20R (PMX Cartridge)
MeSH:Shock, Septic Endotoxemia Sepsis Coronavirus Infections Severe Acute Respiratory Syndrome Shock
HPO:Sepsis


2 SQuISH-COVID: A Pilot Study

This is a single-site prospective study to evaluate the diagnostic performance of the investigational SeptiScan System for patients presenting to the Emergency Department with signs or suspicion of COVID-19 or other infectious respiratory diseases.

NCT04372472 Sepsis COVID-19
MeSH:Sepsis
HPO:Sepsis

Primary Outcomes

Description: The SeptiScan System is an investigational microfluidic assay that measures the biophysical properties of human leukocytes as an aid, in conjunction with other clinical assessments, to detect life-threatening organ dysfunction caused by a dysregulated host immune response to infection. The SeptiScan System score is presented in three Interpretation Bands of low, intermediate, and high probability of disease. Remnant blood samples will be obtained from subjects in Emergency Department with signs or suspicion of COVID-19 or other infectious respiratory diseases. The blood samples will be analyzed using the SeptiScan System.

Measure: To demonstrate the performance of the SeptiScan System as a diagnostic marker of life-threatening organ dysfunction caused by a dysregulated host immune response to infection.

Time: Day of enrollment through Day 5

3 A DB, Placebo-Controlled, Two-Arm Parallel-Group, Phase 3 RCT to Investigate the Efficacy and Safety of Recombinant Human Alkaline Phosphatase for Treatment of Patients With SA-AKI

Clinical phase 3 study to investigate the effect of recAP on 28 day mortality in patients admitted to the ICU with acute kidney injury that is caused by sepsis. 1400 patients will be included in the study that is conducted in approx. 100 ICU's in Europe and North America There are two arms in the study, one with active treatment and one with an inactive compound (placebo). Treatment is by 1 hour intravenous infusion, for three days. Patients are followed up for 28 days to see if there is an improvement on mortality, and followed for 90 and 180 days for mortality and other outcomes e.g. long-term kidney function and quality of life.

NCT04411472 Acute Kidney Injury Due to Sepsis Biological: Recombinant human alkaline phosphatase Other: Placebo
MeSH:Sepsis Acute Kidney Injury
HPO:Acute kidney injury Sepsis

Primary Outcomes

Description: To demonstrate an effect of recAP on 28 day all cause mortality

Measure: 28-day all-cause mortality

Time: 28 days

Secondary Outcomes

Description: MAKE 90: dead or on RRT or ≥25% decline in estimated glomerular filtration rate (eGFR) on Day 90 relative to the known or assumed pre-AKI reference level.

Measure: To investigate the effect of recAP on long-term Major Adverse Kidney Events (MAKE).

Time: 90 Days

Description: Days alive and free of organ support through Day 28, i.e., days alive with no MV, RRT, vasopressors or inotropes (with death within 28 days counting as zero days).

Measure: To investigate the effect of recAP on use of organ support, i.e., mechanical ventilation (MV), Renal Replacement Therapy (RRT), vasopressors or inotropes.

Time: 28 days

Description: Days alive and out of the ICU through Day 28 (with death within 28 days counting as zero days).

Measure: To investigate the effect of recAP on length of stay (LOS) in ICU.

Time: 28 days

Description: Time to death through Day 90.

Measure: To investigate the effect of recAP on 90-day allcause mortality

Time: 90 days


HPO Nodes